Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
MAXZIDE is a fixed-dose combination oral tablet containing hydrochlorothiazide (thiazide diuretic) and triamterene (potassium-sparing diuretic) approved in 1984. It is indicated for hypertension management by combining a sodium-excreting diuretic with a potassium-retaining agent to balance electrolyte effects. The synergistic mechanism reduces blood pressure while minimizing hypokalemia risk associated with thiazide monotherapy.
Product is nearing loss of exclusivity with moderate competitive pressure (30%), indicating team contraction and focus shift toward generic transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MAXZIDE offers limited career advancement potential given its LOE-approaching status and minimal linked job openings. This role suits professionals seeking experience in late-lifecycle management, generic transition planning, or cost-optimization initiatives rather than growth-focused commercial roles.
Worked on MAXZIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.